In HNSCC, GAL2R promotes tumor angiogenesis by enhancing the secretion of cytokines (vascular endothelial growth factor, interleukin-6) via the p38-MAPK-mediated inhibition of tristetraprolin [201]. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.